-+ 0.00%
-+ 0.00%
-+ 0.00%

ADMA Biologics wins FDA nod expanding ASCENIV label to immune-compromised children 2+

PUBT·05/04/2026 11:05:07
Listen to the news
ADMA Biologics wins FDA nod expanding ASCENIV label to immune-compromised children 2+
  • FDA cleared ADMA Biologics’ supplemental BLA for ASCENIV, expanding US labeling to include pediatric primary humoral immunodeficiency patients aged 2 years and older.
  • Labeling change lowers prior age cutoff from 12 years, widening eligible patient population for the IVIG product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040700PRIMZONEFULLFEED9712136) on May 04, 2026, and is solely responsible for the information contained therein.